Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference
This article was originally published in PharmAsia News
SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24
You may also be interested in...
SHANGHAI - China's oncology market is one of the fastest-growing subsectors with cancer now the second-leading cause of death in China. Although the cost of oncology drugs is often prohibitive, increased biomarker testing could help increase access to innovative cancer treatments in China
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
SINGAPORE - European drug maker Sanofi-Aventis is scouting for Asia-centric joint ventures or collaborative arrangements to accelerate its presence in the biosimilars space. Sanofi is hoping to make up ground as some of its global peers have advanced in the segment to capitalize on some of the biggest revenue drivers expected to unfold in the next five to eight years